Dulaglutide for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Dec 2024: Trial registered, NCT06739122
  2. 10 Jan 2025: Trial started, NCT06739122

The trials

NCT06739122: A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

State
Under way
Phase
Phase 3
People
55 planned
Started
10 Jan 2025
Primary completion
Dec 2027
Arms
Dulaglutide
Results
None posted
  1. 18 Dec 2024: Trial registered
  2. 10 Jan 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Trulicity component dulaglutide.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.